107 related articles for article (PubMed ID: 7582256)
1. Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma.
Shawler DL; Dorigo O; Gjerset RA; Royston I; Sobol RE; Fakhrai H
J Immunother Emphasis Tumor Immunol; 1995 May; 17(4):201-8. PubMed ID: 7582256
[TBL] [Abstract][Full Text] [Related]
2. Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity.
Fakhrai H; Shawler DL; Gjerset R; Naviaux RK; Koziol J; Royston I; Sobol RE
Hum Gene Ther; 1995 May; 6(5):591-601. PubMed ID: 7578396
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of retroviral vectors for interleukin-2 gene therapy.
Fakhrai H; Shawler DL; Van Beveren C; Lin H; Dorigo O; Solomon MJ; Gjerset RA; Smith L; Bartholomew RM; Boggiano CA; Gold DP; Sobol RE
J Immunother; 1997 Nov; 20(6):437-48. PubMed ID: 9409449
[TBL] [Abstract][Full Text] [Related]
4. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts.
Tsai SC; Gansbacher B; Tait L; Miller FR; Heppner GH
J Natl Cancer Inst; 1993 Apr; 85(7):546-53. PubMed ID: 8455201
[TBL] [Abstract][Full Text] [Related]
5. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
Tahara H; Zeh HJ; Storkus WJ; Pappo I; Watkins SC; Gubler U; Wolf SF; Robbins PD; Lotze MT
Cancer Res; 1994 Jan; 54(1):182-9. PubMed ID: 7903204
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of interleukin-2 gene-modified fibroblasts in an orthotopic colon cancer model.
Terasawa H; Tanimura H; Nakamori M; Tsunoda T; Iwahashi M; Tani M; Yamaue H
Jpn J Cancer Res; 1999 Sep; 90(9):1000-6. PubMed ID: 10551331
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma.
Shawler D; Dorigo O; Vanbeveren C; Bartholomew R; Fakhrai H; Sobol R
Oncol Rep; 1997; 4(1):135-8. PubMed ID: 21590028
[TBL] [Abstract][Full Text] [Related]
8. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.
Pippin BA; Rosenstein M; Jacob WF; Chiang Y; Lotze MT
Cancer Gene Ther; 1994 Mar; 1(1):35-42. PubMed ID: 7621236
[TBL] [Abstract][Full Text] [Related]
9. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
[TBL] [Abstract][Full Text] [Related]
10. Human lung tumor cell secretion of interleukin-2 for protection against tumor engraftment.
Alosco T; Gansbacher B; Bankert R; Takita H; Petrelli N
Ann Surg Oncol; 1994 May; 1(3):229-35. PubMed ID: 7842293
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models.
Tüting T; Gambotto A; Baar J; Davis ID; Storkus WJ; Zavodny PJ; Narula S; Tahara H; Robbins PD; Lotze MT
Gene Ther; 1997 Oct; 4(10):1053-60. PubMed ID: 9415311
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor effects of bone marrow transplantation in combination with fibroblast-mediated IL-2 and IL-3 gene therapy.
Cao X; Li Q; Ju DW; Wang Q; Tao Q; Wang J
Transplantation; 1999 May; 67(9):1242-50. PubMed ID: 10342316
[TBL] [Abstract][Full Text] [Related]
14. Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells.
Sharma S; Miller PW; Stolina M; Zhu L; Huang M; Paul RW; Dubinett SM
Gene Ther; 1997 Dec; 4(12):1361-70. PubMed ID: 9472560
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model.
Matsumoto G; Sunamura M; Shimamura H; Kodama T; Hashimoto W; Kobari M; Kato K; Takeda K; Yagita H; Okumura K; Hamada H; Matsuno S
Surgery; 1999 Mar; 125(3):257-64. PubMed ID: 10076609
[TBL] [Abstract][Full Text] [Related]
16. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors.
Ram Z; Walbridge S; Heiss JD; Culver KW; Blaese RM; Oldfield EH
J Neurosurg; 1994 Mar; 80(3):535-40. PubMed ID: 8113867
[TBL] [Abstract][Full Text] [Related]
17. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
Carr-Brendel V; Markovic D; Ferrer K; Smith M; Taylor-Papadimitriou J; Cohen EP
Cancer Res; 2000 May; 60(9):2435-43. PubMed ID: 10811121
[TBL] [Abstract][Full Text] [Related]
18. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
19. Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL-2 gene-modified Lewis lung carcinoma cells.
Heike Y; Takahashi M; Ohira T; Naruse I; Hama S; Ohe Y; Kasai T; Fukumoto H; Olsen KJ; Podack EE; Saijo N
Int J Cancer; 1997 Dec; 73(6):844-9. PubMed ID: 9399664
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
